Loncar China BioPharma ETF
CHNA
CHNA was delisted on the 20th of October, 2023.
3 hedge funds and large institutions have $45K invested in Loncar China BioPharma ETF in 2022 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
50% more capital invested
Capital invested by funds: $30K → $45K (+$15K)
0% more funds holding
Funds holding: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$14.9K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $32K | +$14.9K | +806 | +99% |
|
|
BBPWM
2
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $9K | – | – | – |
|
3
Morgan Stanley
New York
| $4K | – | – | – |
|
CHNA Hedge Fund Activity: Q2 2022 in Review
3 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q2 2022, worth a combined $45K — up 50% from $30K a quarter earlier.
Fund positioning in CHNA was balanced in Q2 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $14.9K.
- 3 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $45K of Loncar China BioPharma ETF stock for Q2 2022, up 50% quarter-over-quarter.
- 0 funds opened new Loncar China BioPharma ETF positions in Q2 2022 and 0 closed out.
- The largest Loncar China BioPharma ETF buyer in Q2 2022 was UBS Group, an estimated $14.9K added.
Based on aggregated 13F filings for Q2 2022.